• Inducing Dormancy in Early Embryonic Cells via mTOR Inhibiti

  2026-07-16

  The referenced protocol details a robust in vitro method for inducing a reversible, diapause-like dormant state in mammalian blastocysts and pluripotent stem cells through pharmacological mTOR inhibition. This advance enables high-throughput, noninvasive studies of embryonic dormancy mechanisms and paves the way for improved reproductive research models and translational applications.

• I-BET-762 BET Inhibitor: Optimizing Ferroptosis Assays in Ca

  2026-07-15

  I-BET-762 is redefining BET inhibitor workflows by synergizing with ferroptosis inducers for enhanced cancer cell death, offering new leverage points for epigenetic, inflammatory, and viability assays. This article breaks down protocol enhancements, troubleshooting, and the latest data-backed strategies that translate reference findings into practical lab outcomes.

• 10074-G5: Applied Workflows for c-Myc Inhibitor Cancer Resea

  2026-07-15

  10074-G5 empowers precise modulation of the c-Myc/Max axis in cancer models, supporting advanced apoptosis, cell cycle, and tumor regression assays. This guide covers stepwise protocols, troubleshooting, and integration of reference insights for reproducible, high-impact research.

• FGFR3 Inhibition with NVP-BGJ398 Phosphate in SLC26A2 Chondr

  2026-07-14

  This study demonstrates that pharmacological inhibition of FGFR3 signaling with NVP-BGJ398 phosphate alleviates skeletal abnormalities in mouse models of SLC26A2-related chondrodysplasia. The findings offer mechanistic and translational insight for targeting FGFR3 in rare skeletal disorders.

• PK/PD Optimization of Tiamulin for Mycoplasma gallisepticum

  2026-07-14

  This article reviews a pivotal study defining the pharmacokinetic and pharmacodynamic (PK/PD) profiles of Tiamulin (Thiamutilin) against Mycoplasma gallisepticum in an experimental chicken infection model. The findings inform optimal dosing strategies critical for effective veterinary treatment and resistance management.

• Enhancing Pharmacokinetic Studies with Phenacetin (SKU B1453

  2026-07-13

  This article guides biomedical researchers and lab technicians in optimizing cell viability and pharmacokinetic assays with Phenacetin (SKU B1453). Scenario-driven Q&As address solubility, reproducibility, and product selection, showing how high-purity Phenacetin from APExBIO supports robust, evidence-based research outcomes.

• CD44-Driven Metabolic Rewiring in IDH-Mutant AML: A Targetab

  2026-07-13

  This study uncovers that CD44-mediated metabolic rewiring is essential for the survival of IDH-mutant acute myeloid leukemia (AML) cells by sustaining NADPH-dependent oncometabolite production. These insights highlight CD44 as a novel, targetable dependency and provide a mechanistic foundation for future combinatorial therapeutic strategies in IDH-mutant AML.

• Self-Amplifying RNA Vaccines: Dose-Sparing and Influenza Imm

  2026-07-12

  This article analyzes a 2026 study demonstrating that self-amplifying RNA (saRNA) vaccines induce superior, durable immune responses and enable significant dose-sparing for seasonal influenza, especially against challenging subtypes such as influenza B. Methodological advances and comparative findings are discussed, contextualized within the broader landscape of RNA modification and translational vaccine optimization.

• Syringin Natural Product: Mechanistic Insights for Next-Gen

  2026-07-10

  Explore the molecular mechanisms and assay strategies enabled by Syringin, a bioactive natural product, for advanced apoptosis and signaling pathway research. This article provides unique insights into protocol design and practical implications that distinguish it from typical RCC-focused content.

• Tigecycline’s Impact: Translational Strategy Against Resista

  2026-07-09

  This thought-leadership piece explores how Tigecycline, a pioneering glycylcycline antibiotic, can be strategically leveraged in translational research to combat multidrug-resistant bacteria. By integrating mechanistic insight, experimental data, and guidance for resistance modeling, it charts a path from molecular rationale to clinical translation—bridging recent genomic surveillance of carbapenem-resistant Enterobacter cloacae with actionable protocol design for next-generation antimicrobial development.

• L-Ornithine: Unraveling Metabolic Triggers of CNS Toxicity

  2026-07-09

  This thought-leadership article explores the pivotal role of L-Ornithine as a mechanistic and strategic linchpin in translational research on ammonia detoxification and CNS toxicity. Drawing on recent advances—including landmark findings on ornithine-mediated regulation of astrocyte glycolysis—this piece provides actionable guidance for researchers seeking to bridge liver–brain metabolic dynamics with experimental rigor, while situating APExBIO’s high-purity (S)-2,5-diaminopentanoic acid at the forefront of next-generation metabolic enzyme assays.

• Acifran: Precision Agonist for Lipid Metabolism Research

  2026-07-08

  Acifran, a selective HM74A/GPR109A and GPR109B agonist, empowers lipid metabolism and metabolic disorder research with structural validation and superior workflow flexibility. Its unique binding profile and stability requirements make it the gold standard among hypolipidemic agents for dissecting lipid signaling pathways.

• NVP-BGJ398 Phosphate: Precision FGFR Inhibition for Cancer a

  2026-07-08

  NVP-BGJ398 phosphate stands out as a highly selective and potent FGFR inhibitor, driving translational advances in both oncology and rare skeletal disorder research. This article details experimental workflows, troubleshooting strategies, and the pivotal innovations enabling robust FGFR pathway interrogation across disease models.

• Sabutoclax as a Pan-Bcl-2 Inhibitor: Enabling Quantitative A

  2026-07-07

  Explore how Sabutoclax, a potent pan-Bcl-2 inhibitor, enables quantitative, mechanism-driven apoptosis signaling analysis in cancer research. This article offers a unique perspective on integrating fractional viability and functional readouts for advanced experimental design.

• Abiraterone Acetate: CYP17 Inhibitor Workflows in Prostate C

  2026-07-07

  Abiraterone acetate, a potent CYP17 inhibitor, empowers advanced in vitro and in vivo prostate cancer research, enabling precise modulation of androgen biosynthesis. This article decodes optimized experimental workflows, highlights 3D spheroid model integration, and delivers hands-on troubleshooting strategies to maximize data reliability.

448 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page